Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.
teaser-1024x654-1

Robenidinum (Robenidine) API Manufacturers & Suppliers

0 verified results
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.

Commercial-scale Suppliers

No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Robenidine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Robenidine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Robenidine | CAS No: 25875-51-8 | GMP-certified suppliers

A medication that controls and prevents coccidiosis in poultry by inhibiting protozoal parasite growth, supporting animal health and reducing economic losses in veterinary applications.

Therapeutic categories

AmidinesAnti-Infective AgentsAntiparasitic AgentsAntiprotozoalsCoccidiostatsGuanidines
Generic name
Robenidine
Molecule type
small molecule
CAS number
25875-51-8
DrugBank ID
DB11542
Approval status
Experimental drug, Vet_approved drug

Product Snapshot

  • Robenidine is an oral small molecule formulation primarily used as a veterinary antimicrobial agent
  • Its main therapeutic use is in the control of coccidiosis in poultry and livestock
  • Robenidine is currently approved for veterinary use and is considered experimental for human applications

Clinical Overview

Robenidine (CAS Number 25875-51-8) is an antimicrobial agent classified primarily as a coccidiostat used in veterinary medicine. Its primary application is in the control and prevention of coccidiosis, a protozoal infection caused by coccidian parasites, which presents a significant health risk and economic burden in poultry production. Robenidine acts by inhibiting the growth and reproductive cycles of these parasites, thereby slowing disease progression and reducing parasitic load in affected animals.

Chemically, robenidine is a chlorobenzene derivative belonging to the class of amidines and guanidines. Although detailed pharmacodynamics and the precise molecular mechanism of action remain to be fully elucidated, its antiparasitic efficacy is linked to interference with metabolic or replicative processes specific to coccidia.

Pharmacokinetic data for robenidine are limited; however, its absorption, distribution, metabolism, and excretion (ADME) parameters are consistent with compounds administered in feed to achieve localized antiparasitic activity in the gastrointestinal tract. Oral administration in poultry is the common route, optimizing exposure at the site of coccidian infection while minimizing systemic circulation.

Safety considerations include its use exclusively in veterinary contexts with appropriate withdrawal periods to prevent residual drug presence in edible tissues. Toxicological profiles indicate that while generally well tolerated in target species at recommended doses, improper use or overdose may pose risks. Monitoring is required to mitigate development of resistance. To address this, robenidine is often used intermittently or rotated with other antimicrobials to delay emergence of resistant strains and sustain therapeutic efficacy.

Robenidine is approved for veterinary use in various regions, although specific registration status varies. It plays a strategic role in integrated coccidiosis control programs within poultry farming.

From an API sourcing perspective, it is important to ensure pharmaceutical-grade quality consistent with veterinary medicinal standards. Suppliers should demonstrate compliance with relevant regulations and provide certificates of analysis confirming identity, purity, and absence of contaminants. Given its widespread veterinary use, robust supply chain reliability and adherence to Good Manufacturing Practice (GMP) are critical for consistent product performance and regulatory compliance.

Identification & chemistry

Generic name Robenidine
Molecule type Small molecule
CAS 25875-51-8
UNII 4888ME6C4E
DrugBank ID DB11542

Formulation & handling

  • Robenidine is a small molecule with low water solubility, favoring oral formulation over injectable routes. Its high logP indicates significant lipophilicity, which may require formulation strategies to enhance bioavailability. As a chlorobenzene derivative used in veterinary applications, handling should consider potential environmental and toxicological factors.

Regulatory status

Robenidine is a type of Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.